Bloomberg: Moderna, BionTech's RNA-based Drugs Are Future of Healthcare
Today may be a doozy of a session. We may see many of our positions yanked lower in a continuation of yesterday's session, which saw the Dow and S&P 500 lose altitude, while the Nasdaq dropped 2.5%.
From what I can tell on from published sources, there are lots of talk about emerging fuel shortages in parts of the southeast, related to the Colonial pipeline cyberattack and shutdown over the weekend.
So we may see a lot of "sell first, ask questions later"-kind of activity today.
It could also be over almost as quickly, depending on the flow of headlines on how fast the Colonial pipeline gets up and going again.
Owning a Stock, Owning a Business
At times like this, it helps me to note the bigger picture to owning a stock. Moderna's a good example since it gets yanked up and down by COVID headlines and by traders' overall bullishness (or nervousness) about the Nasdaq itself.
So I just wanted to pass along this Bloomberg article (click the PDF attachment in case you can't get through the site's paywall).
It's an interesting take on what "messenger RNA" technology from Moderna & Pfizer/BionTech will likely bring us in the future.
I probably don't spend enough time talking about Moderna's pipeline of other drugs, all in various stages of development. The stock tends to get yanked up and down based on various COVID-related headline developments, such as the recent "patent waiver" kerfuffle, and the selling or buying in the Nasdaq itself.
But the bigger story, which is not part of the conversation for owning the stock right now, is all the other virus-related vaccines - from cancer to the flu - that Moderna is working on.
Feel free to peruse the handful of slides below, which I lifted from a "Vaccine Day" presentation that Moderna presented to shareholders and analysts in April.
Sort of presents Moderna's business in a whole different light, I'd say.